SFDA To Severely Penalize Pharma For Non-voluntary Recalls
This article was originally published in PharmAsia News
Executive Summary
China’s recently launched administrative penalty rules for pharma and medical device irregularities emphasize a “severe penalty category” punishment for producing counterfeit or substandard medical devices or drugs that cause serious human damage.